Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com
Research analysts at StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock. RGLS has been the subject of a number of other reports. Leerink Partners restated a “market perform” rating and […]
Research analysts at StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock. RGLS has been the subject of a number of other reports. Leerink Partners restated a “market perform” rating and […]
